Alymsys Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

alymsys

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastické činidlá - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

EndolucinBeta Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

endolucinbeta

itm medical isotopes gmbh - lutetium (177lu) chloride - radionuklidové zobrazovanie - terapeutické rádiofarmaká - endolucinbeta je rádiofarmaceutický prekurzor a nie je určený na priame použitie u pacientov. používa sa iba na rádioaktívne značenie nosičových molekúl, ktoré boli špecificky vyvinuté a povolené na rádioaktívne označenie chloridom lutetiom (177lu).

TachoSil Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

tachosil

corza medical gmbh - ľudský fibrinogén, ľudský trombín - hemostáza, chirurgická - antihemoragiká - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.

Indium (In 111) DTPA injection Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

indium (in 111) dtpa injection

mallinckrodt medical b.v. - kyselina indium (111in) pentetová - 88 - radiopharmaca

Gallium (67Ga) Citrate Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

gallium (67ga) citrate

mallinckrodt medical b.v., holandsko - gálium (67ga) citrát - 88 - radiopharmaca

Technescan LyoMAA Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

technescan lyomaa

mallinckrodt medical b.v., holandsko - technécium (99mtc) makrosalb - 88 - radiopharmaca

balance 1.5% glucose, 1.75 mmol/l calcium Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

balance 1.5% glucose, 1.75 mmol/l calcium

fresenius medical care deutschland gmbh, nemecko - hypertonické roztoky - 87 - varia i

balance 4.25% glucose, 1.75 mmol/l calcium Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

balance 4.25% glucose, 1.75 mmol/l calcium

fresenius medical care deutschland gmbh, nemecko - hypertonické roztoky - 87 - varia i

balance 2.3% glucose, 1.75 mmol/l calcium Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

balance 2.3% glucose, 1.75 mmol/l calcium

fresenius medical care deutschland gmbh, nemecko - hypertonické roztoky - 87 - varia i